Should you buy Compass Therapeutics (CMPX)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
- Rejected Analyst Target Caps Upside→Stable
- Death Cross Recovery As Overbought Bounce→Stable
- Quality Deficit From Cash Burn→Stable
- +2 more pillars — see the Why tab for full reasoning
→ Full pillar scorecard with all 5 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Rejected Analyst Target Caps Upside
Trip ifModeled upside rises above 20% as a revalidated price target replaces the current technical target of $2.24.
- P2Death Cross Recovery As Overbought Bounce
Trip ifMomentum score falls below 5.0, confirming the bounce was a bear-market rally rather than a genuine recovery.
- P3Quality Deficit From Cash Burn
Trip ifQuality score rises above 4.0 from the current 1.2.
- P4Upside Exhausted With No Clear Edge
Trip ifModeled upside rises above 15% as the engine identifies a clear trading edge, replacing the current 0% exhausted reading.
- P5Elevated Short Interest Risk
Trip ifShort interest falls below 10% of float, down from the current 22%.
How the engine reached this verdict
TrendMatrix's engine output for Compass Therapeutics, Inc. (CMPX) is SELL_IF_HOLDING with medium conviction, score 4.3/10 at $2.30. An L1 hard-floor gate blocked the positive-verdict path — Quality below minimum threshold; dimensional pillars cannot lift the engine output above the verdict floor while the L1 gate is active.
The engine's exit framework anchors to a tactical sell band near $2.30, with structural invalidation at $2.13. The asymmetric R:R against a reversal hypothesis is 0.00 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bear side: Concentration risk — Pipeline: tovecimig (lead product candidate); Concentration risk — Counterparty: ABL Bio (tovecimig licensor); DATA_ISSUE: analyst_target_implausible (raw $8.50 vs price $2.29 — ratio 3.7×). Rejected, falling back to technical TP.. Active engine warnings: DATA_ISSUE: analyst_target_implausible (raw $8.50 vs price $2.29 — ratio 3.7×). Rejected, falling back to technical TP., Quality below floor (1.2 < 4.0).
SELL output reflects multiple gate failures; recovery requires a confluence of those gates re-clearing, not a single dimension move.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates CMPX — 10-dimension breakdown →
Bear case
- ▸Concentration risk — Pipeline: tovecimig (lead product candidate)
- ▸Concentration risk — Counterparty: ABL Bio (tovecimig licensor)
- ▸DATA_ISSUE: analyst_target_implausible (raw $8.50 vs price $2.29 — ratio 3.7×). Rejected, falling back to technical TP.